Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Primary liver cancer, particularly hepatocellular carcinoma (HCC), is a highly malignant digestive cancer with significant mortality.
• Traditional treatments for HCC often struggle to eliminate residual cancer cells effectively.
• Tumor microenvironments in HCC can exhibit immune tolerance and suppression, hindering effective anti-cancer responses.

Purpose of the Study:

• To elucidate the mechanisms of immunosuppression in hepatocellular carcinoma.
• To review the rationale and current advancements of major immunotherapeutic strategies for HCC.
• To highlight the potential of immunotherapy in improving HCC treatment outcomes.

Main Methods:

• Review of existing literature on hepatocellular carcinoma immunosuppression.
• Summary of four major immunotherapeutic approaches: adoptive cell therapy, cancer vaccination, immune checkpoint inhibitors, and oncolytic viruses.
• Analysis of the mechanisms and clinical progress of each immunotherapy.

Main Results:

• Immunotherapy offers a promising approach for HCC by overcoming immune suppression in the tumor microenvironment.
• Adoptive cell therapy, cancer vaccination, immune checkpoint inhibitors, and oncolytic viruses represent key immunotherapeutic strategies.
• These methods aim to stimulate or restore anti-tumor immune responses to target and eliminate cancer cells.

Conclusions:

• Understanding HCC immunosuppression is crucial for developing effective immunotherapies.
• Adoptive cell therapy, cancer vaccination, immune checkpoint inhibitors, and oncolytic viruses demonstrate significant potential in managing HCC.
• Immunotherapy offers a safer and more effective alternative for advanced HCC and preventing relapse.